Clinical use of 18F-FDG PET/CT in the differential diagnosis of patients with primary and secondary adenoid cystic carcinoma of the lung: a retrospective cohort study

Xiaolin Sun,Weiqing Gu,Hui Yuan,Siyun Wang,Yang Yang,Laura Evangelista,Liyan Zhang,Lei Jiang
DOI: https://doi.org/10.21037/tlcr-22-509
2022-08-13
Translational Lung Cancer Research
Abstract:Background: Adenoid cystic carcinoma (ACC) of the lung (ACCL) is a rare malignancy and includes primary ACCL (PACCL) and secondary ACCL (SACCL) metastasized from the ACC of the head and neck. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) has been shown to be useful in the differential diagnosis between primary and metastatic lung lesions. This study retrospectively investigated the role of <sup>18</sup>F-FDG PET/CT in combination with clinicopathological findings in the management of patients with primary or secondary ACCL.Methods: Clinicopathological characteristics and <sup>18</sup>F-FDG PET/CT metabolic parameters of 29 patients with PACCL and 11 patients with SACCL with pathological confirmation as gold standard were retrospectively collected. The association between PET/CT metabolic parameters and clinicopathological features was explored. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal maximum standard uptake value (SUV<sub>max</sub>) cut-off value to distinguish PACCL from SACCL. The prognostic value of PET/CT metabolic parameters and clinicopathological features was evaluated by Cox regression analysis.Results: SACCL patients more often presented with multiple ACC lesions in the peripheral lung (81.8% <i>vs.</i> 17.2%, P&lt;0.05) and tended to be asymptomatic compared to patients with PACCL (72.7% versus 27.6%, P&lt;0.05). The SUV<sub>max</sub> was significantly higher in PACCL patients compared to SACCL patients (median 4.4 <i>vs.</i> 2.8, P&lt;0.05). Furthermore, at a cut-off value of 3.2 for SUV<sub>max</sub>, the sensitivity and specificity of <sup>18</sup>F-FDG PET/CT in distinguishing PACCL from SACCL were 82.8% and 72.7%, respectively. Higher SUV<sub>max</sub> of ACCL was observed in patients with clinical symptoms, fewer ACC lesions, or larger tumor size (P&lt;0.05). The median PFS of ACCL patients was 71.1 months, and the 12- and 24-month PFS rates were 96.1% and 91.6%, respectively. Univariate Cox regression analysis showed that SACCL from metastasis, lesions located at the peripheral lung or multiple ACC lesions present in the lung, were associated with poorer PFS (P&lt;0.05). However, multivariate Cox regression analysis showed that none of the variables examined were independent predictors of prognosis.Conclusions: The use of <sup>18</sup>F-FDG PET/CT in combination with assessment of clinicopathological features was helpful in distinguishing PACCL from SACCL, which could provide guidance for clinical decision making.
oncology,respiratory system
What problem does this paper attempt to address?